NCT07139418

Brief Summary

This study aims to examine the predictive value of metastatic gastric mesenteries, which contains metastatic lymph node, in 6 gastric mesenteries; and importantly, to further evaluate the relationship between the number of metastatic gastric mesenteries and prognosis in the gastric cancer patients who received D2+complete mesogastric excision (CME).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
53mo left

Started Oct 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress12%
Oct 2025Aug 2030

First Submitted

Initial submission to the registry

August 17, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 24, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

October 7, 2025

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2027

Expected
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2030

Last Updated

March 11, 2026

Status Verified

March 1, 2026

Enrollment Period

1.9 years

First QC Date

August 17, 2025

Last Update Submit

March 8, 2026

Conditions

Gastric Carcinoma

Keywords

Gastric cancerComplete mesogastric excisionGastric mesenteryLymph node metastasis

Outcome Measures

Primary Outcomes (1)

  • overall survival

    Prognostic impact of lymph node-positive mesenteric count in gastric cancer

    through study completion, an average of 3 year

Study Arms (1)

D2+CME surgery for gastric cancer

D2 lymphadenectomy plus complete mesogastric excision in gastric cancer patients

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who met the above inclusion and exclusion criteria

You may qualify if:

  • Aged older than 18 years and younger than 85 years
  • Primary gastric adenocarcinoma confirmed by preoperative pathology result
  • cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
  • Patients who received gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
  • American Society of Anesthesiologists (ASA) class I, II, or III
  • Written informed consent

You may not qualify if:

  • Negative preoperative biopsy
  • Too late tumour stage or metastasis (cT4b/M1)
  • BMI\>30 kg/m2
  • Total gastrectomy or proximal gastrectomy
  • previous neoadjuvant chemotherapy or radiotherapy
  • Previous upper abdominal surgery
  • Combined with other malignant diseases
  • Reject operation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China

RECRUITING

Related Publications (4)

  • Xie D, Gao C, Lu A, Liu L, Yu C, Hu J, Gong J. Proximal segmentation of the dorsal mesogastrium reveals new anatomical implications for laparoscopic surgery. Sci Rep. 2015 Nov 6;5:16287. doi: 10.1038/srep16287.

    PMID: 26542081RESULT

  • Xie D, Wang Y, Shen J, Hu J, Yin P, Gong J. Detection of carcinoembryonic antigen in peritoneal fluid of patients undergoing laparoscopic distal gastrectomy with complete mesogastric excision. Br J Surg. 2018 Oct;105(11):1471-1479. doi: 10.1002/bjs.10881. Epub 2018 Jul 2.

    PMID: 29964324RESULT

  • Xie D, Liu L, Osaiweran H, Yu C, Sheng F, Gao C, Hu J, Gong J. Detection and Characterization of Metastatic Cancer Cells in the Mesogastrium of Gastric Cancer Patients. PLoS One. 2015 Nov 13;10(11):e0142970. doi: 10.1371/journal.pone.0142970. eCollection 2015.

    PMID: 26566136RESULT

  • Xie D, Shen J, Liu L, Cao B, Wang Y, Qin J, Wu J, Yan Q, Hu Y, Yang C, Cao Z, Hu J, Yin P, Gong J. Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial. Cell Rep Med. 2021 Mar 16;2(3):100217. doi: 10.1016/j.xcrm.2021.100217. eCollection 2021 Mar 16.

    PMID: 33763656RESULT

MeSH Terms

Conditions

Stomach NeoplasmsLymphatic Metastasis

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesStomach DiseasesNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Tao Wang, Ph.d

CONTACT

+86-197-068-2528615002740874@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Month
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

August 17, 2025

First Posted

August 24, 2025

Study Start

October 7, 2025

Primary Completion (Estimated)

August 30, 2027

Study Completion (Estimated)

August 30, 2030

Last Updated

March 11, 2026

Record last verified: 2026-03

Locations

CN(1)